Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

01.02.2016 | konsensusbericht

Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa

verfasst von: a. Univ. Prof. Dr. Michael Stur, Siamak Ansari-Shahrezaei, Anton Haas, Michael Tittl

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist eine meist akut auftretende, exsudative Erkrankung der Makula, die primär junge Männer betrifft, aber auch bei Schwangeren und bei Frauen in der Menopause auftreten kann. In den meisten Fällen kommt es zu einer Spontanremission, die wahrscheinlich durch gezielte Aufklärung des Patienten erleichtert werden kann. Heilt die CCS nicht innerhalb von 3 Monaten ab, sollte die Durchführung einer photodynamischen Therapie mit reduzierter Laser- oder Medikamentendosis erwogen werden. Auf die Verordnung anderer Medikamente sollte verzichtet werden, weil es einerseits keine nachweislich wirksamen Medikamente gibt, andererseits durch Medikamenteneinnahme die wahrscheinlich viel wirksamere Veränderung des Lebensstils in den Hintergrund tritt.
Vorheriger Artikel Der rezidivierende Spontanverschluss – Dynamik eines durchgreifenden Makulaforamens in Korrelation mit dem Glaskörper
Nächster Artikel Ärzteausbildung neu 2015: Facharztausbildung neu im Sonderfach Augenheilkunde und Optometrie an der Universitäts-Augenklinik Graz
Literatur
1.
Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144(1):46–50.PubMedCrossRef
2.
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73.PubMedCrossRef
3.
Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14.PubMedCrossRef
4.
Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.PubMedCentralPubMedCrossRef
5.
Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4):698–703.PubMedCrossRef
6.
Pastor-Idoate S, Pena D, Herreras JM. Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol. 2011;2(3):327–32.PubMedCentralPubMedCrossRef
7.
Miki A, Kondo N, Yanagisawa S, et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.PubMedCrossRef
8.
de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122(3):562–70.PubMedCrossRef
9.
Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3.PubMedCrossRef
10.
Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–13.PubMedCrossRef
11.
Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–4.PubMedCentralPubMedCrossRef
12.
13.
Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.PubMedCrossRef
14.
Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77(2):158–60.PubMedCrossRef
15.
Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.PubMedCrossRef
16.
Lovallo WR, Al’Absi M, Blick K, Whitsett TL, Wilson MF. Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav. 1996;55(3):365–9.PubMedCrossRef
17.
Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154(2):366–75e4.PubMedCrossRef
18.
Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168–73.PubMedCrossRef
19.
Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96(6):854–9.PubMedCrossRef
20.
Framme C, Walter A, Gabler B, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83(2):161–7.PubMedCrossRef
21.
Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1–7. (quiz 137-8).PubMedCrossRef
22.
Quaranta-El Maftouhi M, Maftouhi A E, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160(3):581–7.PubMedCrossRef
23.
Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995;102(5):737–47.PubMedCrossRef
24.
Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65–74.PubMedCrossRef
25.
Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000;129(1):16–20.PubMedCrossRef
26.
Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 2012;153(3):474–80e1.PubMedCrossRef
27.
Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J Ophthalmol. 2014;7(2):350–4.
28.
Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina. 2014;34(4):705–12.PubMed
29.
Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology. 2005;112(5):825–33.PubMedCrossRef
30.
Eandi CM, Piccolino FC, Alovisi C, et al. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8.PubMedCrossRef
31.
Iacono P, Battaglia PM, Papayannis A, et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1889–97.PubMedCrossRef
32.
Yoshioka H, Endo Y, Sugita T. [The study of central serous chorioretinopathy by fluorescein fundus angiography. (I)]. Nihon Ganka Gakkai Zasshi. 1969;73(3):299–305.PubMed
33.
Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41.PubMedCrossRef
34.
Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.PubMedCrossRef
35.
Lafaut BA, De Laey JJ. Indocyanine green angiography in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 1996;262:55–61.PubMed
36.
Shiraki K, Moriwaki M, Matsumoto M, et al. Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol. 1997;21(5):245–53.PubMedCrossRef
37.
Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with Verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.PubMedCentralPubMedCrossRef
38.
Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom Med. 1947;9(2):110–7.PubMedCrossRef
39.
Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics. 1971;12(6):398–401.PubMedCrossRef
40.
Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998;236(8):571–6.PubMedCrossRef
41.
Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–8.PubMedCrossRef
42.
Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995;79(10):922–5.PubMedCentralPubMedCrossRef
43.
Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–3.PubMedCrossRef
44.
Werry H, Arends C. Untersuchung zur Objektivierung von Persönlichkeitsmerkmalen bei Patienten mit Retinopathia centralis serosa. Klin Monatsbl Augenheilkd. 1978;172(3):363–70.PubMed
45.
46.
Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):704–8.PubMedCentralPubMedCrossRef
47.
Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014;2014:631687.PubMedCentralPubMedCrossRef
48.
Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):456–67.PubMed
49.
Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.PubMedCrossRef
50.
51.
Nomura Y, Obata R, Yanagi Y. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(3):245–9.PubMedCrossRef
52.
Cakir M, Cekic O, Yilmaz OF. Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(4):405–8.PubMedCrossRef
53.
Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–34.PubMedCrossRef
54.
Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–40.PubMed
55.
Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.PubMedCrossRef
56.
Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307–14.CrossRef
57.
Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465–70.PubMedCrossRef
58.
Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532–6.PubMedCrossRef
59.
Framme C, Alt C, Schnell S, Brinkmann R, Lin CP. [Selective RPE laser treatment with a scanned cw laser beam in rabbits]. Ophthalmologe. 2005;102(5):491–6.PubMedCrossRef
60.
Elsner H, Porksen E, Klatt C, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1638–45.PubMedCrossRef
61.
Klatt C, Elsner H, Porksen E, et al. [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium]. Ophthalmologe. 2006;103(10):850–5.PubMedCrossRef
62.
Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008;40(9):616–24.PubMedCrossRef
63.
Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95(1):83–8.PubMedCrossRef
64.
Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98.PubMedCrossRef
65.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.PubMedCrossRef
66.
Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136(4):750–2.PubMedCrossRef
67.
Battaglia Parodi M, Pozzo S D, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23(2):235–7.PubMedCrossRef
68.
Rouvas A, Stavrakas P, Theodossiadis PG, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22(3):417–22.PubMedCrossRef
69.
Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond). 2013;27(5):612–20.CrossRef
70.
Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–705.PubMedCrossRef
71.
Gutierrez-Hernandez JC, Martinez-Camarillo JC, Sadda SR. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2015;9(2):109–13.PubMedCrossRef
72.
Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99(8):1070–7.PubMedCrossRef
73.
Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011;89(3):e293–4.PubMedCrossRef
74.
Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784–92e2.PubMedCrossRef
75.
Zhao M, Zhang F, Chen Y, et al. A 50 % vs 30 % dose of Verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–40.PubMedCrossRef
76.
Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–601.PubMedCrossRef
77.
Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: a case series. Oman. J Ophthalmol. 2011;4(2):63–6.
78.
Smretschnig E, Ansari-Shahrezaei S, Moussa S, et al. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32(10):2014–9.PubMedCrossRef
79.
Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond). 2013;27(3):353–62.CrossRef
80.
Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7.PubMedCrossRef
81.
Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose Verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65.PubMedCrossRef
82.
Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93.PubMedCrossRef
83.
Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose Verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30(10):1698–703.PubMedCrossRef
84.
Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–73e1.PubMedCrossRef
85.
Shiode Y, Morizane Y, Kimura S, et al. Comparison of halving the irradiation time or the Verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015. (Epub ahead of print).
86.
Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).
87.
Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15.PubMedCrossRef
88.
Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8.PubMedCrossRef
89.
Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007(303):69–73.
90.
Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006;22(2):145–9.PubMedCrossRef
91.
Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol. 1998;54(6):401–4.PubMed
92.
Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol. 2002;58(6):382–6.PubMed
93.
Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120–3.PubMed
94.
Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903.PubMedCentralPubMedCrossRef
95.
96.
Chong CF, Yang D, Pham TQ, Liu H. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. 2012;2012:pii.
97.
Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):96–101.PubMedCentralPubMed
98.
Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–5.PubMedCrossRef
99.
Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–36.PubMedCrossRef
100.
Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6(1):129–32.PubMedCrossRef
101.
Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014;8(1):70–2.PubMedCrossRef
102.
Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).
103.
Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.PubMedCentralPubMed
104.
Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015. (Epub ahead of print).
105.
Ryan EH, Pulido CM. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retin Cases Brief Rep. 2015;9(3):235–8.PubMedCrossRef
106.
Singh RP, Sears JE, Bedi R, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J Ophthalmol. 2015;8(2):310–4.
107.
Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):439–44.PubMedCrossRef
108.
Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92(6):e488–90.PubMedCrossRef
109.
Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.PubMedCrossRef
110.
Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339–46.CrossRef
111.
Kim DY, Joe SG, Yang SJ, et al. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol. 2015;29(3):160–7.PubMedCentralPubMedCrossRef
112.
Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015;29(6):732–40. (quiz 41).CrossRef
113.
Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842–6.PubMedCrossRef
114.
Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–52.PubMedCrossRef
115.
Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):979–81.PubMedCrossRef
116.
Cunneen TS, Tridgell D. The dexamethasone suppression test for the diagnosis of Cushing syndrome in a patient with central serous chorioretinopathy. Retin Cases Brief Rep. 2013;7(2):143–5.PubMedCrossRef
Metadaten
Titel
Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa
verfasst von
a. Univ. Prof. Dr. Michael Stur
Siamak Ansari-Shahrezaei
Anton Haas
Michael Tittl
Publikationsdatum
01.02.2016
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 1/2016
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-015-0276-3

Weitere Artikel der Ausgabe 1/2016

Corneal epithelial thickness measured by Fourier-domain optical coherence tomography

  • original article

Editorial

  • editorial

Der rezidivierende Spontanverschluss – Dynamik eines durchgreifenden Makulaforamens in Korrelation mit dem Glaskörper

  • fallbericht

Auswertung und Vergleich von kornealen und intraokularen Fremdkörpern an der Universitäts-Augenklinik Graz in den Jahren 2007–2013

  • originalarbeit

Open Access publizieren im „spektrum der augenheilkunde“

  • In eigener Sache

Keratoconus und dessen Behandlung mit Hornhautvernetzung und Kontaktlinsen: ein Überblick

  • Open Access
  • übersichtsartikel